Group 1 - The core point of the news is that Selys Medical experienced a stock price increase of 5.04%, reaching 25.65 CNY per share, with a trading volume of 267 million CNY and a turnover rate of 5.12%, resulting in a total market capitalization of 5.39 billion CNY [1] - Selys Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, and was established on February 23, 2004, with its listing date on October 31, 2016. The company's main business involves centralized marketing and service for medical testing, as well as the agency and independent research, production, and sales of in vitro diagnostic products [1] - The revenue composition of Selys Medical includes IVD business at 39.91%, SPD business at 38.01%, and pure sales at 22.08% [1] Group 2 - From the perspective of the top ten circulating shareholders of Selys Medical, data shows that a fund under Caitong Fund ranks among the top ten shareholders. The Caitong Advantage Industry Rotation Mixed A Fund (011201) entered the top ten shareholders in the second quarter, holding 643,400 shares, which accounts for 0.34% of the circulating shares [2] - The Caitong Advantage Industry Rotation Mixed A Fund (011201) was established on February 9, 2021, with a latest scale of 536 million CNY. Year-to-date returns are 19.74%, ranking 4636 out of 8167 in its category; the one-year return is 22.47%, ranking 4803 out of 8010; and since inception, it has a loss of 27.14% [2]

Group 1 - The core viewpoint of the news is that Sely Medical's stock has increased by 5.02%, reaching a price of 29.89 yuan per share, with a trading volume of 3.09 billion yuan and a turnover rate of 5.02%, resulting in a total market capitalization of 62.81 billion yuan [1] - Sely Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, and was established on February 23, 2004, with its listing date on October 31, 2016. The company's main business includes centralized marketing and service for medical testing, agency for in vitro diagnostic products, and research, production, and sales of self-developed in vitro diagnostic products [1] - The revenue composition of Sely Medical's main business is as follows: IVD business accounts for 39.91%, SPD business accounts for 38.01%, and pure sales account for 22.08% [1] Group 2 - From the perspective of Sely Medical's top ten circulating shareholders, a fund under Caitong Fund ranks among the top shareholders. Caitong Advantage Industry Rotation Mixed A (011201) entered the top ten circulating shareholders in the second quarter, holding 643,400 shares, which accounts for 0.34% of the circulating shares. The estimated floating profit today is approximately 920,100 yuan [2] - Caitong Advantage Industry Rotation Mixed A (011201) was established on February 9, 2021, with a latest scale of 536 million yuan. Year-to-date return is 27.92%, ranking 2916 out of 8174 in its category; the one-year return is 47.03%, ranking 3325 out of 7981; and since inception, it has a loss of 22.16% [2]

AI基金财通优势行业轮动混合A（011201）披露2025年一季报，第一季度基金利润789.48万元，加权平均基金份额本期利润0.0091元。报告期内，基金净值 增长率为1.38%，截至一季度末，基金规模为5.26亿元。 该基金属于偏股混合型基金。截至4月24日，单位净值为0.59元。基金经理是张胤，目前管理5只基金。其中，截至4月24日，财通医药健康混合A近一年复权 单位净值增长率最高，达9.57%；财通福盛混合发起(LOF)A最低，为-9.24%。 基金管理人在一季报中表示，在下一季度配置思路上，我们或将关注以下几个重要方向：生物医药：我们看到随着自我保健需求的提升，医保支出在逐渐加 大，医保收支平衡可能面临考验，未来医保控费压力可能会持续存在。长线来看，中国的医疗需求增长、支付能力提升（医保增长+消费升级）和弹性退休 制度的推行或将助推医药需求的快速增长。但短期来看，院内消费和OTC端都会受到医保支付的较大压力，而创新药由于与院内销售关系较小，且已有产权 出海趋势，因此我们认为创新药会更受到投资者的认可。下一阶段我们将继续重点关注：面向全球输出的创新药及医疗器械，这些领域有望迎来布局机会。 通信及半导体 ...